Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Takeda (TAK) Shows Strong Efficacy of Zasocitinib in Psoriasis Trial
Is Arcus Biosciences (RCUS) Using the ROSETTA Trial Tie-Up to Quietly Reframe Its RCC Strategy?
Takeda's TYK2 inhibitor beats BMS' Sotyktu in psoriasis showdown
Deutsche Bank AG Buys 226,088 Shares of Bristol Myers Squibb Company $BMY
M Holdings Securities Inc. Buys Shares of 44,462 Bristol Myers Squibb Company $BMY - Stock Observer
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
Camzyos Priority Review And New Oncology Data Could Be A Game Changer For Bristol-Myers Squibb (BMY)
WINTON GROUP Ltd Takes Position in Bristol Myers Squibb Company $BMY - Zolmax
Motley Fool Asset Management LLC Purchases 50,403 Shares of Bristol Myers Squibb Company $BMY - Stock Observer
Bristol Myers Squibb Company $BMY Stock Holdings Raised by Cerity Partners LLC
Cytospire Therapeutics Appoints Samit Hirawat, M.D., as Non-Executive Director
Bristol Myers Squibb Company $BMY Shares Bought by Cerity Partners LLC - Stock Observer
How New Lung Cancer Data for Pumitamig Could Reshape BioNTech's (BNTX) Post-Vaccine Investment Story
Erste Asset Management GmbH Reduces Stock Holdings in Bristol Myers Squibb Company $BMY - Daily Political
[Trending] Cancer Medicine Market Size Expected to Hit USD 279.87 Billion by 2034, With 12.51% CAGR
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study
Bristol-Myers Squibb Company (BMY) Featured in Citrini's Bullish Healthcare Basket
BMY DCF Analysis: Intrinsic Value $74 vs Price $56
Waddell & Associates LLC Grows Stock Holdings in Bristol Myers Squibb Company $BMY
Bristol Myers Squibb Company $BMY Position Increased by Waddell & Associates LLC - Zolmax
Bristol Myers Squibb Company $BMY Shares Bought by Focus Partners Advisor Solutions LLC - Zolmax
Franklin Resources Inc. Decreases Stock Holdings in Bristol Myers Squibb Company $BMY
Bristol Myers Squibb Company $BMY Shares Acquired by O Shaughnessy Asset Management LLC
Bristol Myers Squibb Company $BMY Shares Acquired by Focus Partners Advisor Solutions LLC
Brandywine Global Investment Management LLC Purchases 52,782 Shares of Bristol Myers Squibb Company $BMY
Mariska Hargitay Partners with Bristol Myers Squibb for "Investigating Myeloma" Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease | Morningstar
Capital International Inc. CA Decreases Stock Position in Bristol Myers Squibb Company $BMY
Bristol Myers Squibb Company $BMY Shares Sold by Capital International Sarl - Daily Political
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial
Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities
Forget Wall Street's Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now
Vise Technologies Inc. Purchases 18,547 Shares of Bristol Myers Squibb Company $BMY
Vise Technologies Inc. Grows Stock Holdings in Bristol Myers Squibb Company $BMY
Bristol Myers Squibb Company $BMY Position Lessened by TD Asset Management Inc
Bristol Myers Squibb (NYSE:BMY) Downgraded by Wall Street Zen to "Buy"
Assessing Bristol Myers Squibb (BMY) Valuation After Fresh EU Opdivo Approval And New Phase 3 Oncology Data
Bristol Myers Squibb Company $BMY Shares Purchased by Natixis Advisors LLC
WCG Wealth Advisors LLC Has $2.56 Million Holdings in Bristol Myers Squibb Company $BMY - Stock Observer
Cibc World Market Inc. Has $26.92 Million Position in Bristol Myers Squibb Company $BMY
Bristol Myers Squibb Company $BMY Shares Sold by Arrowpoint Investment Partners Singapore Pte. Ltd. - Zolmax
UBS Remains a Buy on Olema Pharmaceuticals (OLMA)
Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab
3 Value Stocks We Think Twice About
Sivia Capital Partners LLC Raises Position in Bristol Myers Squibb Company $BMY
Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
CIBC Asset Management Inc Buys 196,274 Shares of Bristol Myers Squibb Company $BMY
Bristol Myers Squibb (BMY) Is Down 6.2% After EU Opdivo Frontline Hodgkin Lymphoma Approval - What's Changed - Simply Wall St News
Westpac Banking Corp Purchases 46,386 Shares of Bristol Myers Squibb Company $BMY
Bank of New York Mellon Corp Has $1.32 Billion Stock Position in Bristol Myers Squibb Company $BMY
Rothschild Wealth LLC Purchases New Stake in Bristol Myers Squibb Company $BMY - Daily Political
Westpac Banking Corp Raises Stock Position in Bristol Myers Squibb Company $BMY - Daily Political
BMS patents new CAMK2 inhibitors | BioWorld
Is Bristol-Myers Squibb Stock Underperforming the Dow?
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - Daily Political
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY)
BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating
BMY: Positive Interim Results for Bristol Myers' Iza-bren in Can
Is BMY Undervalued? DCF Says Worth $74
BMS' bispecific ADC puts TROP2 drugs on notice
ASCO 2026: Transitioning from PD - 1 Replication to "Defining the Next - Generation Framework" in China's Immunotherapy: Three Routes
Promising Pharmaceutical Stocks To Follow Now - June 1st - Zolmax
Bristol Myers Squibb CEO on $15B deal with China's Hengrui Pharma
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) | Morningstar
Sfmg LLC Decreases Stake in Bristol Myers Squibb Company $BMY
Bristol Myers Squibb CEO warns Australia risks losing access to life-saving medicines, must reform Pharmaceutical Benefits Scheme
MUFG Securities EMEA plc Raises Holdings in Bristol Myers Squibb Company $BMY
Black Swift Group LLC Purchases New Position in Bristol Myers Squibb Company $BMY
Peapack Gladstone Financial Corp Has $24.27 Million Stake in Bristol Myers Squibb Company $BMY - Daily Political
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Evaluating the Clinical and Humanistic Impact of a Self-Care and Minor Ailment Service (MAS)
BMY: Promising Phase 2 Results for Pumitamig in Lung Cancer Treatment
BMY Shows Promising Results in Lung Cancer Trial
Railway Pension Investments Ltd Has $63.89 Million Stock Holdings in Bristol Myers Squibb Company $BMY
Impact Partnership Wealth LLC Cuts Stake in Bristol Myers Squibb Company $BMY - Zolmax
Bristol Myers Squibb Company $BMY Shares Sold by Impact Partnership Wealth LLC
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains
Eurizon Capital SGR S.p.A. Takes $82.35 Million Position in Bristol Myers Squibb Company $BMY - Zolmax
Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY
Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial | Valuespectrum.com
C4 Therapeutics (CCCC) Hits 52-Week High Following BMY Trial Success
BMY: New Insights from Bristol Myers Squibb's Phase 3 Cancer Tri
Bristol Myers drug delays myeloma progression in hard to treat patients
SBI Okasan Asset Management Co.Ltd. Takes $1.19 Million Position in Bristol Myers Squibb Company $BMY
Ilmarinen Mutual Pension Insurance Co Decreases Stake in Bristol Myers Squibb Company $BMY
Intech Investment Management LLC Acquires 931,322 Shares of Bristol Myers Squibb Company $BMY
Bristol-Myers Squibb (BMY) Partners with Anthropic
BMS' mezigdomide doubles PFS in multiple myeloma | BioWorld
BristolMyers News
Japanese Tungsten Hexafluoride Production Halt Disrupts Global Semiconductor Supply Chain
Phased Economic Pressure on Iran: A Strategy to Reopen the Strait of Hormuz
US Strikes Iran Again: Military Pressure Falls Short of Diplomatic Breakthrough
Hormuz Strait Reopens: Shifting Oil Market Dynamics and OPEC's Weakening Grip
Oracle Exceeds Q4 Expectations Driven by AI, but Massive Capex Sparks Investor Concerns
US CPI Preview: Higher Inflation Could Reinforce Fed Rate-Hike Bets
CFD Trading Strategies: How to Cash In on the World Cup Stock Market Curse with CFD Shorts
Latest news
Show moreUS Labor Statistics Nominee Affirms Data Integrity Amid Funding and Participation Challenges
As SpaceX, OpenAI, and Anthropic Approach IPOs: New Capital Flows and Sector Reshaping
UAE-Iran High-Level Talks Signal Shift Towards Regional De-escalation Amidst Tensions
SK Hynix Pivots NAND Competition to Material Innovation with 375-Layer Chip
